NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Vyne Therapeutics Inc. VYNE
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$570,000
▲ 13.8% vs FY2024
EPS · FY25
$-0.62
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-66.3%
Net margin · FY25
-4646.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 570,000.00
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 4646 cents on every revenue dollar this year.
Per share
USD -0.62
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-66.3%
Return on equity, FY2025
ROE
Operating margin-5219.1%
Net margin-4646.1%
Return on assets-54.6%
Each USD of equity lost 66 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−51.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+6.1%
−51.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 30.2M
total assets, end of FY2025
Total assetsUSD 30.2M
EquityUSD 27.8M
CashUSD 24.0M
Gross debtUSD 0.00
Net debtUSD -24.0M
Current ratio12.53×
The company holds more cash than debt.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.3
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.3
−0.1
−0.1
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.3
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.62
−0.93
−2.78
−7.28
−25.64
−7.88
11.22
11.47
−5.69
−2.82
−0.97
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−66.3
−56.6
−47.4
−58.1
−170.3
−928.2
−173.4
−92.3
−148.5
·
·
Shares out B
0.03
0.01
0.01
0.00
0.00
0.04
0.01
0.02
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed